Literature DB >> 11563253

Pain management in the critically ill child.

M Yaster1, D G Nichols.   

Abstract

Children frequently received no treatment, or inadequate treatment, for pain and for painful procedures. The newborn and critically ill children are especially vulnerable to no treatment or under-treatment. Nerve pathways essential for the transmission and perception of pain are present and functioning by 24 weeks of gestation. The failure to provide analgesia for pain results in rewiring the nerve pathways responsible for pain transmission in the dorsal horn of the spinal cord and results in increased pain perception for future painful results. Many children would withdraw or deny their pain in an attempt to avoid yet another terrifying and painful experiences, such as the intramuscular injections. Societal fears of opioid addiction and lack of advocacy are also causal factors in the under-treatment of pediatric pain. False beliefs about addictions and proper use of acetaminophen and other analgesics resulted in the failure to provide analgesia to children. All children even the newborn and critically ill require analgesia for pain and painful procedures. Unbelieved pain interferes with sleep, leads to fatigue and a sense of helplessness, and may result in increased morbidity or mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563253     DOI: 10.1007/bf02752416

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  198 in total

1.  Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion.

Authors:  J H Arnold; R D Truog; J M Scavone; T Fenton
Journal:  J Pediatr       Date:  1991-10       Impact factor: 4.406

Review 2.  The significance of multiple CNS opioid receptor types: a review of critical considerations relating to technical details and anatomy in the study of central opioid actions.

Authors:  P L Wood
Journal:  Peptides       Date:  1988       Impact factor: 3.750

3.  Antifungal and immunoadjuvant properties of fluconazole in mice immunosuppressed with morphine.

Authors:  P Di Francesco; R Gaziano; I A Casalinuovo; A T Palamara; C Favalli; E Garaci
Journal:  Chemotherapy       Date:  1997 May-Jun       Impact factor: 2.544

4.  The pharmacokinetics of propofol in children using three different data analysis approaches.

Authors:  B K Kataria; S A Ved; H F Nicodemus; G R Hoy; D Lea; M Y Dubois; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

5.  Inhibitory effects of propofol on cytochrome P450 activities in rat hepatic microsomes.

Authors:  M T Baker; M V Chadam; W C Ronnenberg
Journal:  Anesth Analg       Date:  1993-04       Impact factor: 5.108

Review 6.  Propofol infusion syndrome in children.

Authors:  R J Bray
Journal:  Paediatr Anaesth       Date:  1998       Impact factor: 2.556

7.  Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants.

Authors:  O Dagan; J Klein; D Bohn; G Koren
Journal:  Crit Care Med       Date:  1994-07       Impact factor: 7.598

8.  Postoperative pain control with methadone: influence of supplementary methadone doses and blood concentration--response relationships.

Authors:  G K Gourlay; R J Willis; P R Wilson
Journal:  Anesthesiology       Date:  1984-07       Impact factor: 7.892

9.  Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers.

Authors:  M P Yeager; T A Colacchio; C T Yu; L Hildebrandt; A L Howell; J Weiss; P M Guyre
Journal:  Anesthesiology       Date:  1995-09       Impact factor: 7.892

10.  Human cytochrome P450 mono-oxygenase system is suppressed by propofol.

Authors:  T L Chen; T H Ueng; S H Chen; P H Lee; S Z Fan; C C Liu
Journal:  Br J Anaesth       Date:  1995-05       Impact factor: 9.166

View more
  1 in total

1.  Pain response in newborns to the order of injecting BCG and Hepatitis-B vaccines: a randomized trial.

Authors:  S R Ravikiran; P M Jagadeesh Kumar; Anand D Meundi
Journal:  Indian J Pediatr       Date:  2010-12-31       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.